Kumiko Nagashima
Overview
Explore the profile of Kumiko Nagashima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Severyn B, Nguyen T, Altman M, Li L, Nagashima K, Naumov G, et al.
J Biomol Screen
. 2016 Jul;
21(9):989-97.
PMID: 27461835
The RAS-MAPK pathway controls many cellular programs, including cell proliferation, differentiation, and apoptosis. In colorectal cancers, recurrent mutations in this pathway often lead to increased cell signaling that may contribute...
2.
Muvaffak A, Pan Q, Yan H, Fernandez R, Lim J, Dolinski B, et al.
Mol Cancer Res
. 2014 Apr;
12(7):1055-66.
PMID: 24752990
Unlabelled: TBK1 (TANK-binding kinase 1) is a noncanonical IκB protein kinase that phosphorylates and activates downstream targets such as IRF3 and c-Rel and, mediates NF-κB activation in cancer. Previous reports...
3.
Lafaille J, Nagashima K, Katsuki M, Tonegawa S
J Immunol
. 2013 Mar;
190(7):3028-37.
PMID: 23526828
No abstract available.
4.
Paweletz C, Andersen J, Pollock R, Nagashima K, Hayashi M, Yu S, et al.
PLoS One
. 2011 Nov;
6(10):e26459.
PMID: 22039492
Pharmacodynamic (PD) biomarkers are an increasingly valuable tool for decision-making and prioritization of lead compounds during preclinical and clinical studies as they link drug-target inhibition in cells with biological activity....
5.
Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, et al.
Cancer Res
. 2011 Apr;
71(8):3052-65.
PMID: 21493594
PDK1 activates AKT suggesting that PDK1 inhibition might suppress tumor development. However, while PDK1 has been investigated intensively as an oncology target, selective inhibitors suitable for in vivo studies have...
6.
Nagashima K, Shumway S, Sathyanarayanan S, Chen A, Dolinski B, Xu Y, et al.
J Biol Chem
. 2010 Dec;
286(8):6433-48.
PMID: 21118801
Phosphoinositide-dependent kinase 1 (PDK1) is a critical activator of multiple prosurvival and oncogenic protein kinases and has garnered considerable interest as an oncology drug target. Despite progress characterizing PDK1 as...
7.
Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, et al.
BMC Med Genomics
. 2010 Jul;
3:26.
PMID: 20591134
Background: Hyperactivation of the Ras signaling pathway is a driver of many cancers, and RAS pathway activation can predict response to targeted therapies. Therefore, optimal methods for measuring Ras pathway...
8.
Xu Z, Nagashima K, Sun D, Rush T, Northrup A, Andersen J, et al.
J Biomol Screen
. 2009 Oct;
14(10):1257-62.
PMID: 19822882
The PI3K/Akt signaling pathway plays a key role in cancer cell growth, survival, and tumor angiogenesis. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) is a Ser/Thr protein kinase, which catalyzes the phosphorylation...
9.
Kubota K, Anjum R, Yu Y, Kunz R, Andersen J, Kraus M, et al.
Nat Biotechnol
. 2009 Oct;
27(10):933-40.
PMID: 19801977
Constitutive activation of one or more kinase signaling pathways is a hallmark of many cancers. Here we extend the previously described mass spectrometry-based KAYAK approach by monitoring kinase activities from...
10.
Nagashima K, Sasseville V, Wen D, Bielecki A, Yang H, Simpson C, et al.
Blood
. 2006 Jan;
107(11):4266-73.
PMID: 16439676
The transcription factor NF-kappaB plays a central role in regulating inflammation and apoptosis, making it a compelling target for drug development. We identified a small molecule inhibitor (ML120B) that specifically...